Atara Biotherapeutics Inc. (ATRA) COO Gad Soffer Sells 9,582 Shares
Atara Biotherapeutics Inc. (NASDAQ:ATRA) COO Gad Soffer sold 9,582 shares of the business’s stock in a transaction on Monday, November 14th. The stock was sold at an average price of $20.55, for a total transaction of $196,910.10. Following the transaction, the chief operating officer now owns 225,667 shares of the company’s stock, valued at approximately $4,637,456.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Gad Soffer also recently made the following trade(s):
- On Wednesday, November 16th, Gad Soffer sold 16,718 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $334,360.00.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded down 1.89% on Thursday, reaching $18.15. 95,993 shares of the company traded hands. Atara Biotherapeutics Inc. has a 12 month low of $12.45 and a 12 month high of $40.80. The company’s market capitalization is $523.83 billion. The company has a 50-day moving average price of $16.98 and a 200-day moving average price of $19.56.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Friday, November 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.10. Equities research analysts expect that Atara Biotherapeutics Inc. will post ($3.05) EPS for the current year.
ATRA has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 26th. Jefferies Group initiated coverage on shares of Atara Biotherapeutics in a research note on Monday, October 24th. They issued a “buy” rating and a $23.00 price objective for the company. Goldman Sachs Group Inc. downgraded shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $23.00 to $16.00 in a research note on Thursday, September 15th. Citigroup Inc. upped their price objective on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research note on Friday, August 19th. Finally, Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Sunday, November 6th. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of “Hold” and a consensus price target of $25.86.
Several large investors have recently added to or reduced their stakes in ATRA. Credit Suisse AG increased its stake in Atara Biotherapeutics by 1.8% in the third quarter. Credit Suisse AG now owns 20,935 shares of the company’s stock valued at $447,000 after buying an additional 369 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in Atara Biotherapeutics during the third quarter valued at $110,000. The Manufacturers Life Insurance Company bought a new stake in Atara Biotherapeutics during the third quarter valued at $352,000. Morgan Stanley increased its stake in Atara Biotherapeutics by 102.9% in the third quarter. Morgan Stanley now owns 7,672 shares of the company’s stock valued at $164,000 after buying an additional 3,891 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Atara Biotherapeutics by 4.4% in the third quarter. Northern Trust Corp now owns 251,244 shares of the company’s stock valued at $5,374,000 after buying an additional 10,509 shares during the last quarter. 74.91% of the stock is owned by institutional investors.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.